Brown Brothers Harriman & Co. trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 16.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 177,073 shares of the biopharmaceutical company's stock after selling 33,854 shares during the period. Brown Brothers Harriman & Co.'s holdings in Pfizer were worth $4,698,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the stock. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Bank of America reiterated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.
Check Out Our Latest Analysis on Pfizer
Insider Transactions at Pfizer
In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company's stock.
Pfizer Trading Down 3.0 %
NYSE:PFE traded down $0.77 during trading hours on Tuesday, reaching $24.58. 37,496,261 shares of the company were exchanged, compared to its average volume of 39,095,544. The firm has a market cap of $139.38 billion, a price-to-earnings ratio of 17.44, a PEG ratio of 0.64 and a beta of 0.61. The stock has a 50 day simple moving average of $26.05 and a 200 day simple moving average of $26.88. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company posted $0.10 EPS. The business's quarterly revenue was up 24.7% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
